Novel therapy based on camelid nanobodies-Reference-Cited by-同舟云学术

Novel therapy based on camelid nanobodies

Published:2013-10 Issue:10 Volume:4 Page:1321-1336
ISSN:2041-5990
Container-title:Therapeutic Delivery
language:en
Short-container-title:Therapeutic Delivery

Author:

Unciti-Broceta Juan Diego¹²,Del Castillo Teresa¹²,Soriano Miguel³⁴,Magez Stefan⁵⁶,Garcia-Salcedo Jose A⁷

Affiliation:

1. Unidad de Enfermedades Infecciosas, Hospital Clínico San Cecilio, Instituto de Investigación Biosanitaria de Granada, Av. Dr. Olóriz 16, 18012 Granada, Spain

2. Instituto de Parasitología y Biomedicina ‘López Neyra’ (IPBLN-CSIC), Av. del Conocimiento s/n, 18100, Armilla, Spain

3. GENYO, Centro de Genómica e Investigación Oncológica: Pfizer/Universidad de Granada/Junta de Andalucía, PTS Granada, Spain

4. Departamento de Agronomía, Universidad de Almería. Ctra, Sacramento s/n, La Cañada de San Urbano 04120 Almería, Spain

5. Unit of Cellular & Molecular Immunology, Vrije Universiteit Brussel. Building E Pleinlaan 2 1050, Brussels, Belgium

6. Department of Structural Biology, VIB. Building E, Pleinlaan 2 1050, Brussels, Belgium

7. Unidad de Enfermedades Infecciosas, Hospital Clínico San Cecilio, Instituto de Investigación Biosanitaria de Granada, Av. Dr. Olóriz 16, 18012 Granada, Spain.

Abstract

Nanobodies (Nbs) are small antibody fragments derived from camelid heavy chain antibodies through recombinant gene technology. Their exceptional physicochemical properties, possibility of humanization and unique antigen recognition properties make them excellent candidates for targeted delivery of biologically active components. Several different therapeutic approaches based on the novel camelid Nbs have been developed to treat a wide range of diseases ranging from immune, bone, blood and neurological disorders; infectious diseases and cancer. This review provides a comprehensive overview of the current state of the use of camelid-derived Nbs as novel therapeutic agents against multiple diseases.

Publisher

Future Science Ltd

Subject

Pharmaceutical Science

Link

http://www.future-science.com/doi/pdf/10.4155/tde.13.87

Reference151 articles.

1. Structure and Heterogeneity of Antibodies

2. Somatic generation of antibody diversity

3. Anatomy of the antibody molecule

4. Heavy chain disease—A new disorder of serum γ-globulins

5. Naturally occurring antibodies devoid of light chains

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and Production of a Novel Anti-PD-1 Nanobody by CDR Grafting and Site-Directed Mutagenesis Approach;Molecular Biotechnology;2024-05-12

2. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology;Journal of Translational Medicine;2024-04-12

3. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy;Cell Death & Disease;2024-01-08

4. Combined effect of chitosan loaded with lactoferricin and antibody against Staphylococcus aureus and Pseudomonas aeruginosa;Biologia;2023-11-13

5. Functional integration of protein A binding ability to antibody fragments for convenient and tag-free purification;Bioengineered;2023-09-21